Table of Content

1. Introduction to Bispecific Antibody
1.1 Overview
1.2 Clinical Advancement of Bispecific Antibodies


2. Commercially Approved Bispecific Antibodies Insight: Company, Indication, Location & MOA


3. Global & Regional Bispecific Antibody Market Outlook (2018 till Q1’2023)
3.1 Yearly & Quarterly Sales Insight
3.2 Approved Bispecific Antibodies Reimbursement Policy
3.3 Global Bispecific Antibody Market Forecast 2028


4. Global Bispecific Antibody Market Trends
4.1 US
4.2 Europe
4.3 China
4.4 UK
4.5 Japan
4.6 South Korea
4.7 Australia
4.8 Canada
4.9 Latin America


5. Blincyto: 1st Approved Bispecific Antibody
5.1 Overview & Patent Insight
5.2 Pricing & Dosage Analysis
5.3 Sales Analysis


6. Hemlibra: 2nd Approved Bispecific Antibody
6.1 Overview
6.2 Dosage & Price Analysis
6.3 Sales Analysis


7. Rybrevant: 3rd Approved Bispecific Antibody
7.1 Overview
7.2 Dosage & Price Analysis
7.3 Sales Analysis


8. Kimmtrak: 4th Approved Bispecific Antibody
8.1 Overview
8.2 Pricing & Dosage Insight
8.3 Sales Analysis


9. Vabysmo: 5th Approved Bispecific Antibody
9.1 Overview
9.2 Dosage & Price Analysis
9.3 Sales Analysis


10. Lunsumio: 6th Approved Bispecific Antibody
10.1 Overview & Patent Insight
10.2 Dosage & Price Analysis
10.3 Sales Analysis


11. Cadonilimab: 7th Approved Bispecific Antibody


12. Tecvayli: 8th Approved Bispecific Antibody
12.1 Overview & Patent Insight
12.2 Pricing & Dosage Insight


13. Columvi: 9th Approved Bispecific Antibody


14. Global Bispecific Antibodies Clinical Pipeline Overview
14.1 By Phase
14.2 By Country/Region
14.3 By Company
14.4 By Indication
14.5 Orphan Designated Bispecific Antibodies
14.6 Patient Segment


15. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
15.1 Research
15.2 Preclinical
15.3 Phase-I
15.4 Phase-I/II
15.5 Phase-II
15.6 Phase-II/III
15.7 Phase-III
15.8 Preregistration


16. Marketed Bispecific Antibodies Clinical Insight


17. Competitive Landscape
17.1 ABL Bio
17.2 Abzyme Therapeutics
17.3 Affimed Therapeutics
17.4 Akeso Biopharma
17.5 Alligator Bioscience
17.6 Amgen
17.7 Antibody Therapeutics
17.8 APITBIO
17.9 Aptevo Therapeutics
17.10 Astellas Pharma
17.11 AstraZeneca
17.12 BioAtla
17.13 Biosion
17.14 Biotheus
17.15 BJ Bioscience
17.16 EpimAb Biotherapeutics
17.17 FutureGen Biopharmaceutical
17.18 Genentech
17.19 Genmab
17.20 Gensun Biopharma
17.21 Harbour BioMed
17.22 IGM Biosciences
17.23 I-MAB Biopharma
17.24 ImmuneOnco Biopharma
17.25 ImmunoPrecise Antibodies
17.26 Innovent Biologics
17.27 Invenra
17.28 Janssen Biotech
17.29 Janssen Research & Development
17.30 Kenjockety Biotechnology
17.31 L and L Biopharma
17.32 LaNova Medicines Limited
17.33 Light Chain Bioscience
17.34 Linton Pharm
17.35 Lyvgen Biopharma
17.36 MacroGenics
17.37 Merus
17.38 NovaRock Biotherapeutics
17.39 OriCell Therapeutics
17.40 Pfizer
17.41 Phanes Therapeutics
17.42 Prestige BioPharma
17.43 Regeneron Pharmaceuticals
17.44 Revitope
17.45 Roche
17.46 Virtuoso Therapeutics
17.47 Xencor
17.48 Y-Biologics
17.49 Zhejiang Shimai Pharmaceutical
17.50 Zymeworks



List of Tables

Table 2-1: Approved Bispecific Antibodies

Table 4-1: US – FDA IND Applications Accepted, May’2023
Table 4-2: Bispecific Antibodies In Late Stage Clinical Trials In Different Regions Of European Union
Table 4-3: Bispecific Antibodies Under Clinical Trials In Latin America, May’2023

Table 5-1: Blincyto – Active Patents
Table 5-2: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Table 5-3: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 5-4: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL

Table 7-1: Rybrevant – Premedication
Table 7-2: Rybrevant - Dose Reductions for Adverse Reactions
Table 7-3: Rybrevant - Recommended Dosage Modifications for Adverse Reactions

Table 8-1: Kimmtrak - Recommended Dosage for Treatment of Unresectable or Metastatic Uveal Melanoma
Table 8-2: Kimmtrak - Dose Modifications for Adverse Reactions

Table 10-1: Lunsumio – Treatment Cycles
Table 10-2: Lunsumio - Premedications
Table 10-3: Lunsumio - Recommendations for Management of Cytokine Release Syndrome

Table 12-1: Tecvayli - Dosing Schedule
Table 12-2: Tecvayli - Recommended Dosage Modifications for Adverse Reactions